BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Micrologix Biotech Inc. (MGIXF) Conference Call Notification - MBI 594AN Phase IIb Results


10/19/2005 5:10:46 PM

VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ -- Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) has scheduled a conference call and web cast for Monday, November 17, 2003 at 9:00 a.m. ET (6:00 a.m. PT) to discuss results from the Phase IIb clinical trial of MBI 594AN. It is anticipated that the results of the trial will be released prior to the conference call.

About the Conference Call

To participate in the conference call, please dial 416-405-9328 or 1-800- 387-6216. The call will be available for replay until December 1, 2003 by calling 1-800-408-3053 or 416-695-5800 and entering the pass code 1498266. The live or archived web cast can be accessed through the company's website at http://www.mbiotech.com/.

About Micrologix

Micrologix Biotech Inc. is engaged in the research, development, and commercialization of drugs that advance therapy, improve health, and enrich lives. The Company's focus is toward anti-infective drug development with three product candidates in human clinical studies, multiple product opportunities in preclinical development, and several early-stage technologies in various stages of research and evaluation.

Investor & Media Relations Contacts: Jonathan Burke Micrologix Biotech Inc. Telephone: 604.221.9666 Extension 241 Toll-Free: 1.800.665.1968 E-mail: jburke@mbiotech.com Shayne Payne/Dian Griesel, Ph.D The Investor Relations Group Telephone: 212-825-3210 Email: theproteam@aol.com

Micrologix Biotech Inc.

CONTACT: Investor & Media Relations Contacts: Jonathan Burke, MicrologixBiotech Inc., Telephone: 604-221-9666 Extension 241, Toll-Free:1-800-665-1968, E-mail: jburke@mbiotech.com; Shayne Payne/Dian Griesel,Ph.D, The Investor Relations Group, Telephone: 212-825-3210, Email:theproteam@aol.com;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES